Monte Rosa Q2 net loss narrows to $12.3M on $23.2M collaboration revenue; cash runway to 2028

Monte Rosa Therapeutics, Inc.

Collaboration revenue $23.2M (vs $4.7M YoY) from Novartis license; net loss improved to $12.3M from $30.3M.
R&D $30.7M, G&A $8.1M; cash $295.5M (down $35.5M from Q1), expected to fund into 2028.
Phase 1 of NEK7-directed MGD MRT-8102 dosed; initial data expected H1 2026 for inflammatory diseases.
MRT-6160 advancing toward multiple Phase 2 studies with Novartis; potential milestones up to $2.1B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.